Industrial Partners

Moorfields Eye Hospital - Advanced Cell Technology collaboration in new retinal stem cell trial for Stargardt's Macular Dystrophy

On 23 January 2012, Advanced Cell Technology (ACT) announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells.  The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London.

More at UCL Institute of Ophthalmology and ACT

On 22 September 2011, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) gave the go-ahead to new trials of an experimental retinal stem cell treatment for young patients suffering from Stargardt's Macular Dystrophy, to be performed at Moorfields Eye Hospital. 

Read the Moorfield's Eye Hospital press release

Read the ACT press release

Professor James Bainbridge

UCL-Astra Zeneca to develop regenerative medicines for diabetic retinopathy

On 13 September 2010, AstraZeneca and UCL entered into a collaboration to develop stem cell therapies for diabetic retinopathy, a major cause of visual impairment and blindness worldwide.

Read more at UCL News

UCL–Pfizer to develop pioneering stem cell sight therapies

On 24 April 2009, the London Project to Cure Blindness led by Professor Pete Coffey entered a collaboration with Pfizer to advance the development of stem cell-based therapies for age-related macular degeneration.

Read more at UCL News
diseased eye

Page last modified on 23 jan 12 14:41